What Is an Allogeneic Stem Cell Transplant?

An allogeneic stem cell transplant replaces a person’s blood-forming system with healthy stem cells from a donor. It is one of the most intensive treatments in medicine, used primarily for blood cancers and certain bone marrow disorders that cannot be cured with chemotherapy or radiation alone. The transplant works not just by providing fresh stem cells but by delivering a new immune system capable of attacking residual disease. That dual function, rebuilding the marrow and mounting an immune attack against cancer, is what makes allogeneic transplant uniquely powerful and uniquely risky.

When Doctors Recommend It

The most common reason for an allogeneic transplant is acute myeloid leukemia, particularly in patients whose disease carries genetic features that predict a poor response to chemotherapy alone. European and North American guidelines recommend transplant during a first remission for patients with adverse-risk or most intermediate-risk AML, based on the genetic and molecular profile of the leukemia. Patients with favorable-risk AML are generally spared transplant unless there are signs that residual disease is not clearing adequately.¹ The procedure is also used for acute lymphoblastic leukemia, myelodysplastic syndromes, certain lymphomas, severe aplastic anemia, and some inherited immune or blood disorders like sickle cell disease and thalassemia. Recommendations are updated regularly as new data emerge and as competing treatments, including CAR-T cell therapy, expand into areas that once belonged exclusively to transplant.²

Finding a Donor

Donor matching revolves around human leukocyte antigen (HLA) typing, a set of proteins on cell surfaces that the immune system uses to distinguish “self” from “foreign.” The best match is typically an HLA-identical sibling, someone who inherited the same HLA genes from both parents. Because each sibling has roughly a one-in-four chance of being a full match, many patients have no matched sibling available and turn to volunteer registries, where millions of unrelated donors are typed and searchable.

The five major HLA gene regions that matter most are HLA-A, -B, -C, -DR, and -DQ. An ideal unrelated donor matches at all of these. Additional factors, including compatibility at the HLA-DP region, donor age and sex, cytomegalovirus (CMV) status, and blood group, also influence outcomes. Donors who are half-matched, known as haploidentical donors, share only about half the HLA genes with the recipient. Both haploidentical donors and unrelated donors with a single HLA mismatch are now considered viable alternatives, though they carry roughly a 10% higher risk of mortality compared to fully matched donors.³

Outcomes have improved across all donor types over the past two decades, driven largely by lower rates of death from transplant-related causes rather than better disease control. Three-year survival with a matched sibling donor now sits around 55%, with matched unrelated donors close behind. Haploidentical transplants have shown some of the steepest gains, with three-year survival climbing from roughly 35% to about 44% in the most recent era studied.⁴ The expansion of haploidentical transplant has been a game-changer for patients from underrepresented ethnic backgrounds, who are less likely to find a fully matched unrelated donor in registries. Nearly everyone has at least one haploidentical relative, whether a parent, child, or half-matched sibling.

Where the Stem Cells Come From

There are three sources of stem cells for an allogeneic transplant: bone marrow harvested from the donor’s hip bones under anesthesia, peripheral blood stem cells collected after the donor receives growth factor injections that push stem cells out of the marrow into the bloodstream, and umbilical cord blood banked at birth. Peripheral blood is the most commonly used source today.

A large trial comparing peripheral blood to bone marrow from unrelated donors found that peripheral blood led to faster engraftment and a lower rate of graft failure (about 3% versus 9%). The trade-off was a higher rate of chronic graft-versus-host disease at two years: roughly 53% with peripheral blood compared to 41% with bone marrow. Rates of acute graft-versus-host disease and relapse did not differ meaningfully between the two.⁵ This is a real tension in clinical decision-making. Faster engraftment means a shorter period of dangerous vulnerability to infection, but more chronic graft-versus-host disease means more long-term complications. The choice often depends on the patient’s disease, fitness, and the transplant center’s experience.

Preparing the Body for Transplant

Before the new stem cells are infused, the patient undergoes a conditioning regimen: a combination of high-dose chemotherapy and sometimes radiation designed to wipe out existing bone marrow, kill residual cancer cells, and suppress the immune system enough to prevent rejection of the donor cells. Conditioning regimens fall along a spectrum of intensity.

Myeloablative conditioning (MAC) is the most intense. It destroys the patient’s bone marrow irreversibly, meaning survival depends entirely on the donor cells engrafting successfully. Reduced-intensity conditioning (RIC) uses lower doses that cause reversible damage to the marrow but still require donor cell support. Non-myeloablative conditioning is gentler still, causing minimal damage to existing blood cell production.⁶

The choice between these matters enormously. Long-term follow-up of a clinical trial in AML and myelodysplastic syndrome patients showed that transplant-related death at four years was about 25% with myeloablative conditioning, compared to roughly 10% with reduced-intensity conditioning. But patients who received reduced-intensity conditioning were far more likely to relapse. Overall survival at four years was better with myeloablative conditioning despite its higher toxicity, because relapse rates in the reduced-intensity arm were so high.⁷ In practice, younger and fitter patients tend to receive myeloablative conditioning, while older patients or those with significant health problems may be offered reduced-intensity regimens as the safer, if less effective, alternative.

Engraftment and the Early Weeks

After conditioning, the donor stem cells are infused through a central venous line, much like a blood transfusion. The cells then need to find their way to the bone marrow, a process called homing. Stem cells in the bloodstream navigate to specific niches within the bone marrow where they anchor and begin to proliferate.⁸ Engraftment, the point at which the new marrow starts producing enough white blood cells to be measurable, typically happens within two to four weeks.

The period between conditioning and engraftment is the most dangerous phase. The patient has virtually no functional immune system and relies on a sterile hospital environment, prophylactic antibiotics, and antifungal and antiviral medications to survive. Graft failure, where the donor cells never take hold or stop working shortly after engraftment, is a feared complication. It can be caused by the recipient’s surviving immune cells rejecting the donor marrow, by antibodies, or by inadequate conditioning. Risk factors include HLA mismatching, reduced-intensity conditioning, blood group incompatibility, and prior sensitization.⁹

Graft-Versus-Host Disease

The single most defining complication of allogeneic transplant is graft-versus-host disease (GVHD), in which the donor’s immune cells recognize the recipient’s tissues as foreign and attack them. It comes in two forms. Acute GVHD typically develops within the first few months and most commonly targets the skin, liver, and gut. The severity is graded from mild (grade I) to life-threatening (grade IV) based on how many organs are involved and how badly they are affected.¹⁰

Chronic GVHD is a different entity that can appear months to years after transplant. It often resembles autoimmune conditions, with symptoms like skin thickening and tightening, dry eyes and mouth, joint stiffness, and organ scarring.¹¹ Researchers have long debated whether chronic GVHD is best understood as an autoimmune process. The clinical overlap with diseases like scleroderma and lupus is striking, and the underlying biology involves a breakdown in immune tolerance that looks similar to what happens in autoimmunity, though the mechanisms differ in important ways.¹² Chronic GVHD is the single largest driver of long-term medical costs after transplant and a major source of disability for survivors.

One strategy to reduce GVHD in haploidentical transplants has been the use of post-transplant cyclophosphamide, a drug given shortly after infusion that selectively kills the rapidly dividing donor T cells most responsible for attacking the recipient’s tissues. This approach has made half-matched transplants feasible on a large scale, with outcomes in some diseases comparable to fully matched transplants.¹³ Another approach involves selectively removing specific T cell subsets from the graft before infusion. Depleting a particular population of T cells known to drive GVHD while preserving other immune cells has shown promise in haploidentical settings.¹⁴

The Graft-Versus-Leukemia Effect

GVHD is destructive, but the same immune response that causes it is also what makes allogeneic transplant work against cancer. Donor immune cells that recognize the recipient’s tissues as foreign also recognize and kill residual leukemia cells. This graft-versus-leukemia effect is the reason allogeneic transplant cures cancers that no amount of chemotherapy can eliminate on its own. Removing T cells from the graft to prevent GVHD also eliminates much of the graft-versus-leukemia benefit, which is why transplant teams walk a constant tightrope between the two.¹⁵

This connection has practical consequences. If a patient relapses after transplant, one option is to infuse additional donor lymphocytes, essentially boosting the immune attack without repeating the entire transplant. This can induce a remission, though it also risks triggering GVHD. Separating the beneficial immune attack from the harmful one remains one of the central challenges in transplant research.

Infections and Immune Recovery

Even after engraftment, the new immune system takes a long time to mature. Innate immunity, the first-response defense against pathogens, recovers relatively quickly. Adaptive immunity, the more targeted system that remembers past infections and responds to vaccines, rebuilds much more slowly.¹⁶ Patients remain vulnerable to infections for months to years after transplant, especially if they develop chronic GVHD and require immunosuppressive medications.

Cytomegalovirus (CMV) is one of the most closely watched infections in this population. Most adults carry CMV without symptoms, but in an immunosuppressed transplant recipient, the virus can reactivate and cause serious organ damage. The approval of the antiviral drug letermovir in 2017 shifted many transplant centers toward giving preventive medication rather than waiting for the virus to reappear before treating. Newer drugs and adoptive T cell therapies, where virus-specific immune cells are grown in a lab and infused into the patient, offer additional options for cases that do not respond to standard antivirals.¹⁷

One nuance that is becoming clearer is that numerical immune recovery and functional immune recovery are not the same thing. A patient’s blood counts may show normal numbers of lymphocytes, but those cells may not respond to threats as robustly as expected. Research using gene expression profiling has found that a large majority of immune response genes that were underperforming at six months after transplant remained underperforming at twelve months, even as cell counts improved substantially.¹⁸ This gap between looking recovered and being recovered is one reason transplant recipients stay on prophylactic medications and infection precautions longer than their blood counts alone might suggest.

Life After Transplant

Surviving the first year is a major milestone, but allogeneic transplant leaves a long trail of potential late effects. These include organ damage to the heart, lungs, kidneys, eyes, and endocrine system; secondary cancers; ongoing infections tied to incomplete immune recovery; fertility problems; and psychosocial challenges including depression, anxiety, and difficulty returning to work or school.¹⁹ Many of these late effects trace directly to chronic GVHD and its treatment with long-term immunosuppression.²⁰ Lifelong follow-up with a team familiar with transplant complications is now standard practice.

The gut microbiome has drawn increasing attention as a factor in transplant outcomes. Studies have found associations between the composition of a patient’s gut bacteria before transplant and the risk of acute GVHD. Specifically, a higher abundance of one bacterial group and lower levels of another were linked to greater GVHD risk, leading researchers to explore whether maintaining certain microbial populations throughout transplant might help prevent the complication.²¹ This is still early-stage science, but it reflects a broader shift toward thinking about the transplant patient as a whole ecosystem rather than just a recipient of donor cells.

Children Versus Adults

Pediatric patients generally fare better after allogeneic transplant than adults. Children tend to have fewer underlying health problems, tolerate intensive conditioning better, and benefit from a more active thymus gland, the organ responsible for training new T cells. This means children rebuild functional immunity faster and may have a stronger graft-versus-leukemia effect. Pediatric leukemias also differ genetically from adult versions in ways that can make them more responsive to treatment after transplant.²²

The psychological burden, however, falls heavily on the families of pediatric patients. Caregivers report intense distress early in the transplant process, worsened by restrictive hospital environments, the demands of constant vigilance, financial strain, and separation from other family members. As care shifts to the outpatient setting, anxiety does not disappear but changes shape, centering on fears of relapse and infection and the challenge of managing complex home care routines while balancing the needs of siblings and partners.²³

The Financial Reality

Allogeneic transplant is extraordinarily expensive. Estimates of lifetime medical costs for a transplant patient range from roughly $940,000 to over $1.2 million. Chronic GVHD treatment alone accounts for somewhere between a third and half of that total, dwarfing the cost of the transplant procedure itself.²⁴ These figures reflect direct medical costs and do not capture lost income, travel, caregiver time, or the less tangible toll of years spent managing a chronic medical condition.

Financial distress is common among transplant recipients. Research has identified perceived income loss after transplant and lower household income as independent predictors of financial hardship, with the burden falling disproportionately on women and lower-income households.²⁵ The psychosocial toll is closely intertwined with the financial one. Patients and families dealing with economic strain after transplant often experience worse mental health outcomes, creating a cycle that transplant teams increasingly recognize they need to address proactively rather than as an afterthought.²⁶

Gene Therapy and the Question of Alternatives

For diseases like sickle cell disease and thalassemia, gene therapy has emerged as a potential alternative to allogeneic transplant. The appeal is obvious: gene therapy uses a patient’s own cells, modified in a laboratory to correct the underlying genetic defect, eliminating the need for a donor and the risk of GVHD entirely. The first gene therapies for sickle cell disease received regulatory approval in late 2023.

The reality, at least so far, is more complicated. Gene therapy currently costs roughly five times more than allogeneic transplant, still requires myeloablative conditioning with its associated toxicities, and carries its own set of safety concerns that only longer follow-up will fully clarify.²⁷ A systematic review comparing the two approaches found that while both reduce disease complications effectively, overall evidence quality remains low, with no randomized trials directly comparing them head to head.²⁸ Allogeneic transplant has decades of outcome data behind it; gene therapy has years at best.

For blood cancers, gene therapy is not a direct competitor to allogeneic transplant in the same way. CAR-T cell therapy, which engineers a patient’s own immune cells to attack cancer, has taken over some indications that previously led to transplant, particularly certain relapsed lymphomas and leukemias. But CAR-T therapy does not rebuild the blood-forming system, and for many patients with high-risk or relapsed disease, allogeneic transplant remains the only realistic shot at long-term cure. The two treatments are increasingly used in sequence rather than as substitutes, with CAR-T therapy sometimes serving as a bridge to transplant.²⁹